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Abstract: Glioblastoma (GBM) patients have an estimated survival of ~15 months with treatment, and
the standard of care only modestly enhances patient survival. Identifying biomarkers representing
vulnerabilities may allow for the selection of efficacious chemotherapy options to address personalized
variations in GBM tumors. Irinotecan targets topoisomerase I (TOP1) by forming a ternary DNA–TOP1
cleavage complex (TOP1cc), inducing apoptosis. Tyrosyl-DNA phosphodiesterase 1 (TDP1) is a
crucial repair enzyme that may reduce the effectiveness of irinotecan. We treated GBM cell lines
with increasing concentrations of irinotecan and compared the IC50 values. We found that the
TDP1/TOP1 activity ratio had the strongest correlation (Pearson correlation coefficient R = 0.972,
based on the average from three sets of experiments) with IC50 values following irinotecan treatment.
Increasing the TDP1/TOP1 activity ratio by the ectopic expression of wild-type TDP1 increased in
irinotecan IC50 , while the expression of the TDP1 catalytic-null mutant did not alter the susceptibility
to irinotecan. The TDP1/TOP1 activity ratio may be a new predictive indicator for GBM vulnerability
to irinotecan, allowing for the selection of individual patients for irinotecan treatment based on
risk–benefit. Moreover, TDP1 inhibitors may be a novel combination treatment with irinotecan to
improve GBM patient responsiveness to genotoxic chemotherapies.
Keywords: topoisomerase; TOP1; TDP1; irinotecan; risk-benefit; predictive indicator
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1. Introduction
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with a
dismal prognosis indicated by a 14.6-month median survival after surgical resection, radiotherapy,
and chemotherapy treatment with temozolomide (TMZ) [1]. Irinotecan (IRT) is used to treat metastatic
colorectal cancer and small cell lung cancer (SCLC) [2,3]. Irinotecan has some capacity to cross the
blood–brain barrier (BBB) [4], and was shown to be effective against recurrent malignant glioma in
early phase II clinical trials [5,6], although other clinical trials could not confirm the activity from
irinotecan monotherapy [7,8]. Studies of irinotecan in combination therapy have yielded modest
activity as well [7,9–11]. These seemingly discrepant results may indicate an underlying variability
in the susceptibility of patients in each trial towards the genotoxic chemotherapy. Thus, to improve
clinical outcomes and minimize toxic side effects, identifying biomarkers for GBM susceptibility to
irinotecan would be instrumental for selecting patients for irinotecan treatment.
Irinotecan, its active metabolite SN-38, and topotecan are chemotherapeutic camptothecin
derivatives (CPTs) acting as topoisomerase I (TOP1) poisons [12] (Figure 1). Human TOP1 is vital
for replication and transcription, as it relaxes DNA superhelical tension through phosphodiester
bond cleavage, strand rotation, and DNA resealing steps [13]. During the DNA cleavage step,
TOP1 covalently attaches to the 3’-end of DNA, with its catalytic tyrosine residue forming reversible
DNA–TOP1 cleavage complexes (TOP1cc). Stabilization of the TOP1cc by TOP1 poisons generates
deleterious single-strand breaks (SSBs) [14]. A collision between the replication fork and TOP1cc
produces DNA double-strand breaks (DSBs) and triggers cell death [15,16]. The lethal TOP1cc can
be trapped by endogenous DNA lesions and oxidative stress-induced base modifications [13,17–19].
Therefore, the irreversible TOP1cc must be countered by the endogenous repair mechanism to preserve
genome integrity [20,21]. Tyrosyl-DNA phosphodiesterase 1 (TDP1) liberates TOP1 peptide from the 3’
end of DNA by hydrolyzing the phosphotyrosyl bond after proteasome-dependent degradation of
TOP1cc [22,23] (Figure 1).
Human TDP1, a member of the phospholipase D (PLD) superfamily, has two crucial catalytic
residues, H263 and H493 [24]. A homozygous TDP1 H493R mutation is associated with familial
spinocerebellar ataxia with axonal neuropathy (SCAN1) [25,26]. Lymphoblastoid cells derived from
SCAN1 patients are hypersensitive to CPTs, resulting from a 25-fold reduction in TDP1 activity [27],
implying that TDP1 activity may suppress the effectiveness of CPTs. Moreover, TDP1 deficiency
in TDP1 knockdown cells confers enhanced cytotoxic response to CPT, whereas the depletion of
TOP1 rescues cells from CPT-induced cell death [28,29]. Additionally, phosphorylation of the TOP1
conserved-core domain (residue 198–651) elevates TOP1 activity, which in turn reduces cellular
resistance to CPT [30,31]. The activity levels of both TOP1 and TDP1 may affect the anticancer efficacy
of TOP1 poisons.
In this study, we measured the protein concentrations and activity of both TOP1 and TDP1 in nine
GBM cell lines. Elevated TOP1 levels and a diminished TDP1 abundance were observed in GBM lines
compared to fetal normal human astrocyte (NHA), but no correlation was observed between TOP1 or
TDP1 levels and irinotecan sensitivity. We examined the relative activities of TDP1 and TOP1 along
with protein levels with respect to drug responses. Our results show that the TDP1/TOP1 activity ratio
has a strong correlation with irinotecan sensitivity. Furthermore, increased TDP1 activity by ectopic
expression of TDP1 in GBM cells conferred increased irinotecan resistance.
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In contrast, established GBM cell lines had lower levels of TDP1 than NHA (Figure 2B), with relative
ratios <1 (Table S1). The IC50 s for individual cell lines towards irinotecan was measured using a
cell-based assay to detect cell abundance (Table 1). No significant correlation (R = −0.254) was found
between TOP1 protein levels and irinotecan IC50 s (Table S2). However, a weak correlation between
higher TDP1 protein levels and increased IC50 values was observed (R = 0.797, p = 0.01; Table S2).
These trends held across three distinct biological replicates (Figure S2, Table S2), suggesting that TOP1
and TDP1 levels alone may not be highly predictive indicators of irinotecan vulnerability.
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2.2. TOP1 Enzymatic Activity in GBM Cell Lines Does not Correspond to the TOP1 Protein Level
TOP1 relaxation activity can be measured using supercoiled plasmid DNA as a substrate [13].
Human TOP1 belongs to the type IB topoisomerase family and does not require ATP or divalent metal
ions for its catalytic activity. Recombinant human TOP1 (hTOP1) protein activity (Figure 3A) was
used to generate a linear standard curve for the increase in the fraction of DNA relaxed with the
increasing level of TOP1 activity (Figure 3B). The TOP1 relaxation activity in each GBM WCE was
assayed with serial dilutions of the WCEs (Figure 3C). The quantified values are shown in Table S3.
Results from additional biological replicates can be found in Figure S3. The relative TOP1 activity level
did not correlate with TOP1 protein concentrations (R = 0.446, Figure S3 and Table S4), suggesting
that TOP1 activity in GBM might be modulated by other means. Also, cell specific TOP1 activities did
not correlate with irinotecan IC50 (Table S2). These studies indicate that TOP1 activity cannot predict
irinotecan toxicity in established GBM cell lines.
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2.3. Measurement of TDP1 Activity in GBM Cell Lines by Gel-Based and Fluorescence-Based Assays
We employed two approaches to measure TDP1 activity in GBM WCEs. Previous studies have
demonstrated that human TDP1 is an ATP- as well as a divalent ion-independent enzyme that can
hydrolyze the phosphotyrosyl-linkage at the 3’ end of DNA without sequence specificity [22,24].
In addition, TDP1 can act as a broad-spectrum 3’ exonuclease which is able to hydrolyze various
phosphodiester linkages at the 3’ ends of DNA [24,32]. The TDP1 activity is efficient on single-stranded
or blunt-ended oligonucleotides [24,32]. To determine TDP1 activity, we used a gel-based assay
with a 5’-32 P labeled single-stranded oligonucleotide with a 3’ tyrosine modification (P12Y) as the
substrate to yield P12 as the TDP1 reaction product in proportion to an increasing amount of
recombinant human TDP1 (Figure 4A). In an alternative fluorescence-based assay, a hairpin-structured
blunt-ended oligonucleotide (Figure 4B) with a 5’ fluorophore and a 3’ BHQ1 modification was used
as a substrate [33]. TDP1 removal of the quencher at the 3’-end of the substrate led to an increase in
fluorescence signal (∆F). Activities in the GBM WCEs, measured in triplicates by the gel-based assay
(Figure 4C) or fluorescence-based assay (Figure 4D), were calculated based on the standard curve of
recombinant human TDP1 (hTDP1) (Figure 4A,B) and normalized to TDP1 activity level in NHA (Table
S5). Results from additional replicates can be found in Figure S4. The TDP1 activities obtained from
the gel-based and fluorescence-based assays showed strong correlations (R = 0.943, Figure S4, panel
D4), demonstrating their similar capabilities for measuring TDP1 activities in vitro. EDTA was present
in both assay buffers to suppress the metal ion-dependent exonuclease activities present in the WCEs.
TDP1 activity levels measured by the two assay methods correlate only slightly with TDP1 protein
levels measured by Western blot (Table S4) and with irinotecan IC50 s (Table S2).
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TOP1 poisons and that loss of TDP1 activity would lead to hypersensitivity to TOP1 poisons [13,22].
However, our results above indicate that TOP1 and TDP1 protein expression levels in GBM could
not accurately predict the TOP1 and TDP1 activity levels, and that the protein level or activity level
of TOP1 and TDP1 individually are not useful indicators of the GBM cellular response to irinotecan.
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between TOP1 and TDP1 protein expression (Table S6) suggests that there
is
no overlapping pathway for regulating TOP1 and TDP1 levels. To further identify more promising
indicators, we calculated the TDP1/TOP1 protein level ratio and the TDP1/TOP1 activity level ratio
(Table S7). The TDP1/TOP1 protein ratios (Figure 5A) were weakly correlated with irinotecan IC50
(Table S7). The TDP1/TOP1 protein ratios (Figure 5A) were weakly correlated with irinotecan IC50 (R
(R = 0.696, p = 0.037; Figure 5B). However, the TDP1/TOP1 activity ratios (Figure 5C) were strongly
= 0.696, p = 0.037; Figure 5B). However, the TDP1/TOP1 activity ratios (Figure 5C) were strongly
correlated with the irinotecan IC50 values (R = 0.917, p = 0.0005 for gel based TDP1 assay; R = 0.922,
correlated with the irinotecan IC50 values (R = 0.917, p = 0.0005 for gel based TDP1 assay; R = 0.922, p
p = 0.0004 for fluorescence based TDP1 assay; Figure 5D). The results from the other two sets of
= 0.0004 for fluorescence based TDP1 assay; Figure 5D). The results from the other two sets of
experiments with the GBM cell lines also confirmed that the TDP1/TOP1 activity ratio is a strong
experiments with the GBM cell lines also confirmed that the TDP1/TOP1 activity ratio is a strong
predictor for irinotecan IC (Figure S5, Table S2), with Pearson correlation coefficient R = 0.972 for the
predictor for irinotecan IC5050 (Figure S5, Table S2), with Pearson correlation coefficient R = 0.972 for
average of the gel-based TDP1/TOP1 activity ratios from all three sets of experiments.
the average of the gel-based TDP1/TOP1 activity ratios from all three sets of experiments.
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2.5. Increased Resistance to Irinotecan Following Transfection with Recombinant TDP1
2.5. Increased Resistance to Irinotecan Following Transfection with Recombinant TDP1
Previous study has already shown that the knockdown of TDP1 activity by siRNA in
rhabdomyosarcoma cell lines or by shRNA in lung fibroblast cell line increases the sensitivity to
CPT [29,34]. Furthermore, TOP1 depletion by siRNA was found to sensitize colorectal cancer cell lines
to irinotecan treatment in a TOP1-dependent manner [28]. To follow up on our observed correlation
between irinotecan sensitivity and the TDP1/TOP1 activity ratio in GBM cell lines, we elevated the TDP1
activity in H4 cell line by transfection with clones expressing wild-type (WT)-TDP1 or null activity
mutant H263A-TDP1 [19] to determine the effect on irinotecan IC50 . The overexpression of TDP1 and
unchanged expression of TOP1 were confirmed by Western blotting (Figure 6A). An increase in TDP1
catalytic activity in the WCE from WT-TDP1 but not H263A-TDP1 was also observed (Figure 6B),
along with no change in TOP1 catalytic activity, as expected. H4 cells transfected with WT-TDP1 had
significantly higher Irinotecan IC50 than H4 cells transfected with the H236A-TDP1 clone (Figure 6C).
This result further supports the correlation between the TDP1/TOP1 activity ratio and Irinotecan IC50
for GBM.

TDP1 and unchanged expression of TOP1 were confirmed by Western blotting (Figure 6A). An
increase in TDP1 catalytic activity in the WCE from WT-TDP1 but not H263A-TDP1 was also
observed (Figure 6B), along with no change in TOP1 catalytic activity, as expected. H4 cells
transfected with WT-TDP1 had significantly higher Irinotecan IC50 than H4 cells transfected with the
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H236A-TDP1
clone (Figure 6C). This result further supports the correlation between the TDP1/TOP1
activity ratio and Irinotecan IC50 for GBM.
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(WT-TDP1) or mutant (H263A-TDP1) clones. Cells were collected 24 h after transfection and 10 µg
of WCEs were analyzed by western blots. Whole blots with molecular weight markers are shown in
Figure S6. The signal from actin was used to control the loading of WCE proteins. Normalized intensity
ratios are given for each band, with the intensity ratio of mock-treated control set as 1. The bar graphs
show the average and standard deviation of measurements as error bars from all technical replicates
(n = 3 or more); (B) TDP1 and TOP1 activity levels in H4 WCE from the transfection of WT-TDP1.
Cells were collected 24 h post-transfection and 4 µg of WCE was used in the gel-based assay for TDP1
activity; (C) Irinotecan IC50 for H4 cells transfected with the WT-TDP1 clone versus H263A mutant
TDP1 clone (n = 7).

Figure S6. The signal from actin was used to control the loading of WCE proteins. Normalized
intensity ratios are given for each band, with the intensity ratio of mock-treated control set as 1. The
bar graphs show the average and standard deviation of measurements as error bars from all technical
replicates (n = 3 or more); (B) TDP1 and TOP1 activity levels in H4 WCE from the transfection of WTTDP1. Cells were collected 24 h post-transfection and 4 µ g of WCE was used in the gel-based assay
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mutant TDP1 clone (n = 7).
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2.6. Carboxylesterase 2 (CES2) Activity in the GBM Cell Lines
Irinotecan is converted to the much more potent metabolite SN-38 by carboxylesterase isoform
Irinotecan is converted to the much more potent metabolite SN-38 by carboxylesterase isoform
CES2 [35]. The CES2 activity present in the GBM cell lines studied here were assayed and found to
CES2 [35]. The CES2 activity present in the GBM cell lines studied here were assayed and found to
be comparable (Figure 7). This demonstrates that the relatively higher level of resistance of cell lines
be comparable (Figure 7). This demonstrates that the relatively higher level of resistance of cell lines
such as A172 and SNB75 to irinotecan was not due to lack of CES2 activity in these cells, and the
such as A172 and SNB75 to irinotecan was not due to lack of CES2 activity in these cells, and the
irinotecan sensitivity of SNB19 was not due to a relatively high level of CES2 being present in SNB19.
irinotecan sensitivity of SNB19 was not due to a relatively high level of CES2 being present in SNB19.
Metabolic conversion of irinotecan to SN-38 could be a significant factor for irinotecan treatment
Metabolic conversion of irinotecan to SN-38 could be a significant factor for irinotecan treatment
efficacy in vivo [36]. Nevertheless, the observation made here that GBM cells with a lower TDP1/TOP1
efficacy in vivo [36]. Nevertheless, the observation made here that GBM cells with a lower
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Figure 8. TOP1 and TDP1 activity and protein levels in GBM patient tumor WCEs. (A) Assay of TOP1
Figure 8. TOP1 and TDP1 activity and protein levels in GBM patient tumor WCEs. (A) Assay of TOP1
activity in GBM patient tumor WCEs; (B) Western blot analysis of TOP1 protein expression. The first
activity in GBM patient tumor WCEs; (B) Western blot analysis of TOP1 protein expression. The first
two panels are from the same blot. Signal from actin was used to control loading of WCE proteins (60
two panels are from the same blot. Signal from actin was used to control loading of WCE proteins
µ g). Normalized intensity ratios are given for each band, with the intensity ratio of NHA set as 1; (C)
(60 µg). Normalized intensity ratios are given for each band, with the intensity ratio of NHA set as
Pearson correlation of relative TOP1 protein and activity levels in GBM patient tumor WCEs; (D)
1; (C) Pearson correlation of relative TOP1 protein and activity levels in GBM patient tumor WCEs;
fluorescence-based assay of TDP1 activity; (E) Western blot analysis of TDP1 protein expression; (F)
(D) fluorescence-based assay of TDP1 activity; (E) Western blot analysis of TDP1 protein expression;
Pearson correlation of relative TDP1 protein and activity levels in GBM patient tumor WCEs. The bar
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3. Discussion
3. Discussion
GBM is a devastating disease with poor prognosis and a lack of predictive biomarkers for
GBM is a devastating disease with poor prognosis and a lack of predictive biomarkers for
chemotherapy [1]. The prodrug irinotecan is converted to a topoisomerase I poison specifically to
chemotherapy [1]. The prodrug irinotecan is converted to a topoisomerase I poison specifically to
stabilize the TOP1cc on chromosomal DNA. Irinotecan has been found in clinical trials to exhibit
stabilize the TOP1cc on chromosomal DNA. Irinotecan has been found in clinical trials to exhibit
modest and not consistently reproducible efficacy in the treatment of GBM. Therefore, our study is
modest and not consistently reproducible efficacy in the treatment of GBM. Therefore, our study is
aimed at evaluating the roles of TOP1 as a target and the TOP1cc repair enzyme TDP1 on the sensitivity
aimed at evaluating the roles of TOP1 as a target and the TOP1cc repair enzyme TDP1 on the
of GBM to irinotecan treatment in order to identify rational predictive biomarkers that may contribute
sensitivity of GBM to irinotecan treatment in order to identify rational predictive biomarkers that
to improving the treatment outcomes.
may contribute to improving the treatment outcomes.
Previous studies have shown that the cytotoxic activity of TOP1 poisons is associated with
Previous studies have shown that the cytotoxic activity of TOP1 poisons is associated with TOP1
TOP1 and TDP1 protein expression, as well as their catalytic activities. The infection of GBM cell
and TDP1 protein expression, as well as their catalytic activities. The infection of GBM cell lines with
lines with adenovirus Delta-24 has been shown to increase the expression and activity of TOP1 and
adenovirus Delta-24 has been shown to increase the expression and activity of TOP1 and enhances
enhances the antiglioma effect of irinotecan [37]. A preliminary study on nine clinical colorectal tumors
the antiglioma effect of irinotecan [37]. A preliminary study on nine clinical colorectal tumors
indicated that the three samples with the highest TOP1 expression and activity were from patients
indicated that the three samples with the highest TOP1 expression and activity were from patients
who responded to irinotecan treatment [38]. Although a later study on the roles of TDP1 and TOP1 in
who responded to irinotecan treatment [38]. Although a later study on the roles of TDP1 and TOP1
modulating colorectal cancer response to irinotecan demonstrated that TDP1 overexpression or TOP1
in modulating colorectal cancer response to irinotecan demonstrated that TDP1 overexpression or
depletion is protective, while conversely TDP1 depletion leads to TOP1-dependent hypersensitivity to
TOP1 depletion is protective, while conversely TDP1 depletion leads to TOP1-dependent
irinotecan, there was no correlation between inherent TDP1 or TOP1 protein levels alone and irinotecan
hypersensitivity to irinotecan, there was no correlation between inherent TDP1 or TOP1 protein
sensitivity [28]. A study on small cell lung cancer (SCLC) cell lines found that TDP1/TOP1 protein
levels alone and irinotecan sensitivity [28]. A study on small cell lung cancer (SCLC) cell lines found
ratio is a better predictor than the individual TDP1 or TOP1 protein level, showing good correlation
that TDP1/TOP1 protein ratio is a better predictor than the individual TDP1 or TOP1 protein level,
with irinotecan sensitivity in eight out of ten cell lines examined [39].
showing good correlation with irinotecan sensitivity in eight out of ten cell lines examined [39].
In our study, we found that the TDP1/TOP1 activity ratio was superior to TDP1/TOP1 protein
In our study, we found that the TDP1/TOP1 activity ratio was superior to TDP1/TOP1 protein
ratio as a predictor for the response of GBM cell lines to irinotecan treatment, as indicated by the
ratio as a predictor for the response of GBM cell lines to irinotecan treatment, as indicated by the
irinotecan IC50 s measured here. This may be due to post-translational modification (PTM) of TOP1
irinotecan IC50s measured here. This may be due to post-translational modification (PTM) of TOP1
and TDP1 proteins in GBM. Previous studies have shown that PTMs can have a significant influence
and TDP1 proteins in GBM. Previous studies have shown that PTMs can have a significant influence
on TOP1 activity and drug cytotoxicity. TOP1 phosphorylation, at the PT268 or PS506 site, increases
on TOP1 activity and drug cytotoxicity. TOP1 phosphorylation, at the PT268 or PS506 site, increases
TOP1 activities and cellular sensitivity to CPT-induced apoptosis [31,40]. O-GlcNAcylation is also
TOP1 activities and cellular sensitivity to CPT-induced apoptosis [31,40]. O-GlcNAcylation is also
found to contribute to the activity elevation of TOP1 [41]. We suggest that the PTMs confer TOP1
found to contribute to the activity elevation of TOP1 [41]. We suggest that the PTMs confer TOP1
activity alterations and might account for the weaker correlation between the TOP1 protein and its
activity alterations and might account for the weaker correlation between the TOP1 protein and its
activity levels in GBM cell lines. A previous study [42] reported enhanced MKP-1 phosphatase activity
activity levels in GBM cell lines. A previous study [42] reported enhanced MKP-1 phosphatase
in GBM cells, including U251, studied here. Knockdown of the MKP-1 was found to enhance cell death
activity in GBM cells, including U251, studied here. Knockdown of the MKP-1 was found to enhance
caused by cancer drugs. The effect on irinotecan-induced cell death was more prominent than other
cell death caused by cancer drugs. The effect on irinotecan-induced cell death was more prominent
drugs. It is possible that MKP-1 phosphatase activity produces a higher TDP1/TOP1 activity ratio
than other drugs. It is possible that MKP-1 phosphatase activity produces a higher TDP1/TOP1
by removing a phosphorylation on TOP1 that can activate the TOP1 activity. Breast cancer cell lines
activity ratio by removing a phosphorylation on TOP1 that can activate the TOP1 activity. Breast
selected for resistance following exposure to irinotecan have been found to have TOP1 with altered
cancer cell lines selected for resistance following exposure to irinotecan have been found to have
isoelectric points, consistent with altered PTMs of TOP1 [43]. In contrast, the lesser influence of PTM
TOP1 with altered isoelectric points, consistent with altered PTMs of TOP1 [43]. In contrast, the lesser
on TDP1 activity might account for the stronger correlation between the TDP1 protein and its activity
influence of PTM on TDP1 activity might account for the stronger correlation between the TDP1
protein and its activity level. In addition to z-scores for irinotecan, drug sensitivity z-scores for
camptothecin and topotecan are also available in the CellMiner database for the six GBM cell lines
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level. In addition to z-scores for irinotecan, drug sensitivity z-scores for camptothecin and topotecan
are also available in the CellMiner database for the six GBM cell lines included in the NCI-60 panel
(Table S10) [44,45]. The sensitivity z-scores for these TOP1 inhibitors all show better correlation with
our TDP1/TOP1 activity ratio than the TDP1/TOP1 protein ratio or TDP1 protein and activity level
alone (Table S11). As expected, there was little or no correlation between TDP1/TOP1 activity ratio and
sensitivity z-scores for TOP2 inhibitors in the CellMiner database (Table S11).
The low expression of TDP1 observed in the GBM cell lines may reflect repair pathway deficiencies
in cancer development. The increase of irinotecan IC50 resulting from the transfection of the GBM
H4 cell line with the recombinant TDP1 clone is consistent with TDP1 activity being an important
determinant of GBM sensitivity to irinotecan treatment. A decrease in TDP1 activity in the U87
cell, by either knockdown or inhibitor, would be expected to decrease the IC50 of this relatively
resistant GBM cell line, as demonstrated previously for other cancer cell lines [28,29,34]. Combination
therapy that targets both TOP1 and TDP1 has great potential to improve the treatment outcomes of
GBM. In addition, TDP1 possesses the versatility of precisely hydrolyzing a variety of 3’ adducts
from DNA [22,32,46,47], and therefore, the screening of TDP1 inhibitors is a promising avenue for
developing new cancer therapies [48–51].
There are additional cellular factors that contribute to irinotecan treatment outcome.
The CPT-induced degradation of TOP1, via the efficient degradation of TOP1cc, is necessary for
sufficient exposure of the phosphodiester linkage to TDP1 hydrolysis [13,52,53]. Previous studies
have shown that DNA damage-induced PTMs are associated with TDP1 N-terminal domain (NTD),
a dispensable domain for TDP1 catalytic activity (residue 1–148). Phosphorylation, SUMOylation, and
PARylation at NTD stabilize TDP1 and promote TDP1 recruitment on the DNA damage site without
interfering with its activity [54–57].
It is worth noting that drug sensitivities are also determined in part by alternative repair pathways
and epigenetic modifications. PNKP and XRCC1 are essential enzymes for single-strand break repair
following the TDP1 repair process [13]. RECQ1, Mus81-EME1, and XPF-ERCC1 could provide
resistance to CPT-induced apoptosis on either single-strand break repair or double-strand break repair
pathways [58–60]. The PARylation of TOP1 reduces its activity in vivo by regulating TOP1 delocalizing
from the nucleolus to nucleoplasm and increases cell resistance [61]. In addition, perturbed histone
acetylation stimulates faster access by DNA repair enzymes to the damaged sites and subsequently
provokes a higher resistance [62], and may have to be considered for the optimization of GBM treatment
in the future.
4. Materials and Methods
4.1. GBM Cell Lines
The GBM cell lines U87, A172, and H4 were obtained from American Type Culture Collection
(ATCC). Cell lines SF295, SF268, SF539, SNB75, SNB19, and U251 were provided by National Cancer
Institute Division of Cancer Treatment and Diagnosis (NCI, DCTD). Cell lines were cultured and
maintained in Dulbecco’s Modified Eagle’s medium (DMEM, Corning Inc., Corning, NY, USA)
supplemented with 10% heat-inactivated fetal bovine serum (Hyclone FBS, Thermo Fisher Scientific,
Waltham, MA, USA), 1% Penicillin-Streptomycin (Thermo Fisher Scientific), and 0.1% Plasmocin
Prophylactic (InvivoGen, San Diego, CA, USA). All cells were grown at 37 ◦ C in a humidified incubator
with 5% CO2 . Human astrocytes were purchased from ScienCell Research Laboratories (Carlsbad,
CA, USA) and cultivated in accordance with the manufacturer’s protocol, using Astrocyte Medium
(ScienCell) on poly-L-lysine-coated cell culture flasks and dishes. Cells were used for only two
subcultures to prevent the analysis of senescent cells.
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4.2. GBM Whole Cell Extract (WCE) Preparation
To prepare WCEs for the analysis of proteins, cells were plated at a density of 4 × 105 cells in 60 mm
dishes and collected until 80% confluence. Briefly, cells were washed twice in 1 × phosphate-buffered
saline (Gibco PBS, Thermo Fisher Scientific) and lysed in radioimmunoprecipitation assay buffer (RIPA,
50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM EGTA, 1% NP-40, 0.1% SDS, and 0.5%
sodium deoxycholate) supplemented with 1 mM phenylmethanesulfonyl fluoride (PMSF), 1% (v/v) of
Halt Protease inhibitor cocktails (Thermo Fisher Scientific), and 1% (v/v) Halt Phosphatase inhibitor
cocktails (Thermo Fisher Scientific). Cells were incubated with lysis buffer on ice for 5 min and then
transferred to a sterile microcentrifuge tube, followed by 30%, 30 s sonication with a Thermo Fisher
Scientific 120 W microtip sonicator. The cell debris was removed by centrifugation at 15,000× g at 4 ◦ C
for 15 min and the supernatant protein concentration was measured using the Pierce BCA Assay Kit
(Thermo Fisher Scientific).
4.3. Western Blots
Protein expression levels were detected using Western blots. Briefly, proteins from whole cell
extracts (WCE) were first separated by 7.5% SDS-PAGE and then transferred to nitrocellulose membrane
with a transfer buffer (48 mM Tris, 39 mM glycine, 0.4% SDS, 20% v/v methanol) at 100 V for 1 h.
The membrane was blocked with 5% bovine serum albumin (BSA) in Tris-buffered saline (TBS) at room
temperature for 1 h, followed by incubation of 1:1000 (v/v) primary antibody diluted in 1% Tween
20 in TBS (TBST) at 4 ◦ C for 18 h. The membrane was washed three times for 5 min (3 × 5 min) and
the horse-radish peroxidase (HRP) conjugated secondary antibody 1:5000 (v/v) diluted in TBST was
incubated with the membrane at room temperature (RT) for an additional 1 h. The membrane was
then washed 3 × 5 min before the target protein expression level was developed with SuperSignal
West Pico Plus Chemiluminescent Substrate (Thermo Fisher) for 5 min. The images were obtained
with a C-DiGit Blot scanner (LI-COR, Lincoln, NE, USA) and the expression density from the target
protein was analyzed by ImageStudio (LI-COR). The information on primary and secondary antibodies
is listed in Table S12. The Western blot TOP1 or TDP1 signal intensity for each GBM cell line WCE
was first normalized to actin signal to correct for loading, then divided by the NHA TOP1 or TDP1
signal intensity for the comparison of relative TOP1 or TDP1 protein levels. GraphPad Prism version
8.1 was used to carry out the data analysis. The mean and standard deviations shown in bar graphs
were calculated based on at least three technical replicates. The degree of correlation between the
two parameters tested was determined by using the Pearson correlation coefficient value (R) and
considered as significant for p < 0.05. Each entire set of experiments was repeated three times.
4.4. Irinotecan IC50 Measurement for GBM Cell Lines
For IC50 measurement of GBM cell lines, cells were plated at a density of 8.5 × 103 cells/well in
a 96-well plate and cultured until 70–80% confluence. Concentrated irinotecan dissolved in DMSO
was serially diluted (0.05 to 15 µM) in freshly prepared culture media, which were used for further
72 h incubation of the cells. The cell viabilities were assayed by TO-PRO-3 Stain (Thermo Fisher
Scientific) according to the manufacturer’s protocol. Briefly, cells were first fixed using 100 µL/well of
4% paraformaldehyde/PBS (PFA) for 20 min at RT and permeated with 0.2% TritonX-100/PBS by a
further 30 min of rocking. Cells were then blocked by the blocking buffer (LI-COR) for 30 min and
stained by adding diluted TO-PRO3 reagent at a ratio of 1:1000 in blocking buffer for an additional 1 h
rocking. Before reading, cells were rinsed four times with 0.1% Tween/PBS. The far-red fluorescence
signal from the TO-PRO3 reagent was detectable by the Odyssey CLx Imaging System (LI-COR) from
surviving cells, which were analyzed by the ImageStudio system (LI-COR). IC50 was determined as
the concentration of irinotecan which results in a 50% of cell viability compared to the DMSO control.
Results were obtained from six technical replicates conducted in each of five biological replicates.
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4.5. Human Topoisomerase I (hTOP1) Relaxation Activity Measurement
Negatively supercoiled pBAD/Thio plasmid DNA (240 ng) purified by cesium chloride gradient
centrifugation was used as the substrate for the hTOP1 relaxation assay. The relaxation assay was
conducted for established GBM cell lines and NHA WCEs in a reaction buffer supplemented with
EDTA to chelate with metal ions and thereby suppress the activities from the metal ion-dependent
type IA and type IIA topoisomerase activities present in the WCE. The reaction was carried out in a
volume of 20 µL in a reaction buffer of 10 mM Tris-HCl, pH 7.9, 1 mM EDTA, 150 mM NaCl, 0.1% BSA,
0.1 mM spermidine, and 5% glycerol. After 30 min at 37 ◦ C, reactions were stopped by adding 4 µL of
6× SDS stop buffer (6% SDS, 0.3% bromophenol blue, 30% glycerol). Supercoiled substrate DNA and
relaxed DNA products were separated based on difference in electrophoretic mobility in 1% agarose
gel. The DNA molecules in the gel were stained with 1 µg/mL of EtBr solution and photographed
over UV light. AlphaView SA) were used to generate a reference standard curve for the fraction of
supercoiled DNA converted to relaxed DNA by units (U) of hTOP1 as defined by the supplier. TOP1
activity in whole cell extracts (WCEs) was assayed under the same conditions. Serial dilutions of
WCEs were assayed to identify the amount needed to relax 50% of the supercoiled DNA substrate and
calculate the hTOP1 activity present in each WCE based on the standard curve as U/µg of total WCE
protein. The relative hTOP1 activity levels present in the cell lines were normalized by the hTOP1
activity level in fetal normal human astrocyte (NHA).
4.6. Human TDP1 Activity Measurement
4.6.1. Gel-Based TDP1 Assay
The 12-base long oligonucleotide substrate linked to tyrosine at the 3’-end
(5’-HO-GAAAAAAGAGTT-PO4-Tyr-3’) was obtained from TopoGEN and labeled at the 5’-end with
(γ-32 P) ATP and T4 polynucleotide kinase (NEB). The radiolabeled oligonucleotide substrate P12Y was
purified by centrifugation through a 1 mL Sephadex G15 column and stored in 10 mM Tris-HCl pH 7.5
at −20 ◦ C until further use. Recombinant human tyrosyl-DNA phosphodiesterase 1 (hTDP1) was
purified as described [63]. Serial dilutions of hTDP1 were incubated with P12Y oligo (4 ng) at 37 ◦ C
for 30 min in 5 µL of reaction buffer (20 mM Tris-HCl, pH 7.5, 100 mM KCl, 10 mM EDTA, 1 mM
DTT). The reaction was stopped by adding 5 µL of 2 × stop solution (96% formamide, 20 mM EDTA,
0.03% xylene cyanol and 0.03% bromophenol blue) followed by heat-inactivation at 95 ◦ C for 5 min.
Oligonucleotide P12 Y substrate and P12 product with 3’-tyrosine removed by hTDP1 were separated
by electrophoresis in 20% urea-denaturing sequencing gel. Following analysis with the BioRad Pharos
FX Plus Phosphorimager, the correlation between hTDP1 activity, represented as fmol, and the fraction
of P12 produced was plotted as a standard curve. TDP1 activity assay for WCE proteins was carried
out under the same conditions, with 2 µg of WCE proteins added to each reaction. The TDP1 activity
present in each microgram of WCE was calculated based on the standard curve as fmol/µg. The TDP1
activities in the GBM cell lines were normalized by TDP1 activity in NHA.
4.6.2. Human TDP1 Activity Measurement by Fluorescence-Based Assay
Human TDP1 (hTDP1) activity was also carried out by fluorescence-based assay as described [33].
The 5’ phosphorothioate bond linked fluorophore, 6-FAM, and 3’ phosphodiester bond linked quencher,
BHQ1, were modifications present on a 55 nucleotides long 5’FAM-DNA-BHQ1-3’ oligonucleotide
substrate (5’-6-FAM-AAA GCA GGC TTC AAC GCA ACT GTG AAG ATC GCT TGG GTG CGT TGA
AGC CTG CTT T-BHQ1-3’, purchased from LGC BioSearch) that formed a hairpin structure. Briefly,
25 pmol of 5’FAM-DNA-BHQ1-3’ was incubated with serial dilutions of hTDP1 at 37 ◦ C in a reaction
buffer of 20 mM Tris-HCl, pH 8.0, 100 mM KCl, 10 mM EDTA, 10 mM DTT, 0.05% TritonX-100, with a
final volume of 25 µL. The fluorescence signal from each reaction was measured every 30 s for 500 min.
The correlation between the amount of hTDP1, present as fmol, and the initial linear slope (0–125 min)
from each reaction was plotted as a standard curve. TDP1 activity present 2 µg of WCE was assayed
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under the same conditions and calculated based on the standard curve as fmol/µg WCE. The relative
TDP1 activity levels in the cell lines were normalized by the TDP1 activity level in NHA.
4.7. Transfection with Wild-Type (WT) and Mutant TDP1 cDNA Clones
The TDP1 cDNA clone with expression under the control of the CMV promoter in pCMV6-XL4 was
obtained from OriGene. H263A substitution was performed using the Q5 Site-Directed Mutagenesis
Kit (NEB) with 5’-TGGAACACACGCCACGAAAATGATG-3’ and 5’-AACGCAATATCCAACTTTG-3’
primers to generate a mutant with null activity [24]. GBM H4 cells were seeded at a density of 1.8
× 105 cells/well in 35 mm dishes and cultured 24 h until 60% confluence. DNA (500 ng) was mixed
with Lipofectamine 3000 (Invitrogen) at a ratio of 1:2 (w/v) in 250 µL of Opti-MEM Medium (Gibco)
for 20 min at RT and added to cells. After further incubation for 24 h, WCEs were prepared using
the RIPA buffer, as described above. For measurement of irinotecan IC50 , H4 cells were plated at
a density of 6.5 × 103 cells/well and cultured for 24 h until 60% confluence. DNA was mixed with
Lipofectamine 3000 in 10 µL of Opti-MEM Medium for 20 min at RT and incubated with cells for 24 h
before the addition of serial dilutions of irinotecan. After further incubation for 72 h, cell viabilities
were measured with the TO-PRO3 assay, as described above.
4.8. Protein Extraction from GBM Patient Samples
Glioblastoma tumors were collected from the patients during operations at the Miami Neuroscience
Center of Larkin Hospital according to the protocol approved by Florida International University
Institutional Review Board (No. IRB-16-0355-CR02), and snap-frozen in cryotubes pre-cooled on dry
ice. Samples kept in dry ice were then delivered by courier to Florida International University and
cryopreserved in liquid nitrogen. Ten GBM tumors were used to prepare WCEs. Frozen tumor tissues
were transferred onto an ice-cooled 100 mm dish and sliced into small pieces. The tumor segments
were then weighed and the RIPA/inhibitors lysis buffer was added at a ratio of 1:10 (v/w). Samples
were homogenized by Dounce Homogenizer and rotated at 4 ◦ C for 2 h, followed by centrifugation at
15,000× g for 15 min. Supernatant was kept in aliquots at –80 ◦ C for further analysis.
4.9. Carboxylesterase 2 Activity Measurement
The carboxylesterase 2 (CES2) activity in each cell line was assayed as described [64] using 6.7 µg
of WCE proteins in the presence or absence of 300 µM of CES2 inhibitor loperamide (MilliporeSigma,
St. Louis, MO, USA) in 20 µL of 100 mM Tris-HCl, pH 7.4 pre-incubated at 37 ◦ C for 10 min.
The reaction was initiated by adding 200 µL of p-NPA (4-Nitrophenyl acetate, MilliporeSigma)
substrate. Absorbance at 405 nm was recorded at 0, 5, 10, 20, 30, 40, 50, and 60 min. The amount of the
reaction product p-NP formed was calculated based on the standard curve from serial dilutions of
p-NP (MilliporeSigma). The carboxylesterase activity from each microgram of WCE was represented
as pmol/min/µg. The difference in activity obtained in the presence and absence of loperamide was
considered CES2 activity. The assay was performed in a total of nine replicates in two experiments.
4.10. Statistical Analysis
The correlation between two parameters was determined using the Pearson correlation coefficient
value (R) and considered significant when the p-value was less than 0.05. The significance of the
difference between the two groups was determined by the pairwise t-test (not significant, p-value > 0.05;
*, p-value 0.01 to 0.05; **, p -value 0.001 to 0.01; ***, p -value 0.0001 to 0.001; ****, p -value < 0.0001).
The bar-graph is presented as average ± standard deviation (SD) as the error bar. GraphPad Prism
version 8.1 was used to carry out the data analysis.
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5. Conclusions
This study demonstrates that the variation in TDP1/TOP1 activity ratio in GBM could be a potential
predictive biomarker for irinotecan treatment. Further study on TDP1 and TOP1 protein expression
and activity in patient-derived GBM models along with clinical outcome is required. Inhibiting TDP1
activity is a plausible approach to improve irinotecan effectiveness in GBM.
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